Huifen Chen

Huifen Chen

Auto-generated profile, based on publicly available information

Huifen Chen

Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ABAlessia Balestrini
Alessia Balestrini
VJVictory Joseph
Victory Joseph
MDMichelle Dourado
Michelle Dourado
RRRebecca M. Reese
Rebecca M. Reese
SSShannon D. Shields
Shannon D. Shields
LRLorena Riol-Blanco
Lorena Riol-Blanco
Despite the development of effective therapies, a substantial proportion of asthmatics continue to have uncontrolled symptoms, airflow limitation, and exacerbations. Transient receptor potential cation channel member A1 (TRPA1) agonists are elevated in human asthmatic airways, and in rodents, TRPA1 is involved in the induction of airway inflammation and hyperreactivity. Here, the discovery and early clinical development of GDC-0334, a highly potent, selective, and orally bioavailable TRPA1 antagonist, is described. GDC-0334 inhibited TRPA1 function on airway smooth muscle and sensory neurons, decreasing edema, dermal blood flow (DBF), cough, and allergic airway inflammation in several preclinical species. In a healthy volunteer Phase 1 study, treatment with GDC-0334 reduced TRPA1 agonist-induced DBF, pain, and itch, demonstrating GDC-0334 target engagement in humans. These data provide therapeutic rationale for evaluating TRPA1 inhibition as a clinical therapy for asthma.

16 May 2012 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
HCHuifen Chen
Huifen Chen
BCBryan K. Chan
Bryan K. Chan
JDJason Drummond
Jason Drummond
AEAnthony A. Estrada
Anthony A. Estrada
JGJanet Gunzner-Toste
Janet Gunzner-Toste
DBDaniel J. Burdick
Daniel J. Burdick

1 August 2022 in BMC Medical Informatics and Decision Making
Verified
Journal Article
Open access
PDF file
NLNuo Lei
Nuo Lei
XZXianlong Zhang
Xianlong Zhang
MWMengting Wei
Mengting Wei
BLBeini Lao
Beini Lao
XXXueyi Xu
Xueyi Xu
YWYi-fan Wu
Yi-fan Wu
Background: Kidney disease progression rates vary among patients. Rapid and accurate prediction of kidney disease outcomes is crucial for disease management. In recent years, various prediction models using Machine Learning (ML) algorithms have been established in nephrology. However, their accuracy have been inconsistent. Therefore, we conducted a systematic review and meta-analysis to investigate the diagnostic accuracy of ML algorithms for kidney disease progression. Methods: We searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials, the Chinese Biomedicine Literature Database, Chinese National Knowledge Infrastructure, Wanfang Database, and the VIP Database for diagnostic studies on ML algorithms’ accuracy in predicting kidney disease prognosis, from the establishment of these databases until October 2020. Two investigators independently evaluate study quality by QUADAS-2 tool and extracted data from single ML algorithm for data synthesis using the bivariate model and the hierarchical summary receiver operating characteristic (HSROC) model. Results: Fifteen studies were left after screening, only 6 studies were eligible for data synthesis. The sample size of these 6 studies was 12,534, and the kidney disease types could be divided into chronic kidney disease (CKD) and Immunoglobulin A Nephropathy, with 5 articles using end-stage renal diseases occurrence as the primary outcome. The main results indicated that the area under curve (AUC) of the HSROC was 0.87 (0.84–0.90) and ML algorithm exhibited a strong specificity, 95% confidence interval and heterogeneity (I2) of (0.87, 0.84–0.90, [I2 99.0%]) and a weak sensitivity of (0.68, 0.58–0.77, [I2 99.7%]) in predicting kidney disease deterioration. And the the results of subgroup analysis indicated that ML algorithm’s AUC for predicting CKD prognosis was 0.82 (0.79–0.85), with the pool sensitivity of (0.64, 0.49–0.77, [I2 99.20%]) and pool specificity of (0.84, 0.74–0.91, [I2 99.84%]). The ML algorithm’s AUC for predicting IgA nephropathy prognosis was 0.78 (0.74–0.81), with the pool sensitivity of (0.74, 0.71–0.77, [I2 7.10%]) and pool specificity of (0.93, 0.91–0.95, [I2 83.92%]). Conclusion: Taking advantage of big data, ML algorithm-based prediction models have high accuracy in predicting kidney disease progression, we recommend ML algorithms as an auxiliary tool for clinicians to determine proper treatment and disease management strategies.

22 March 2021 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JTJack A. Terrett
Jack A. Terrett
HCHuifen Chen
Huifen Chen
DSDaniel G. Shore
Daniel G. Shore
EVElisia Villemure
Elisia Villemure
RLRobin Larouche-Gauthier
Robin Larouche-Gauthier
MVMatthew Volgraf
Matthew Volgraf

25 August 2020 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
HCHuifen Chen
Huifen Chen
JTJack A. Terrett
Jack A. Terrett
TRPA1 is a non-selective cation channel predominantly expressed in sensory neurons, and functions as an irritant sensor for a plethora of noxious external stimuli and endogenous ligands associated ...

5 January 2024 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MBMichael Berlin
Michael Berlin
JCJennifer Cantley
Jennifer Cantley
MBMark Bookbinder
Mark Bookbinder
EBElizabeth Bortolon
Elizabeth Bortolon
FBFabio Broccatelli
Fabio Broccatelli
PDPeter S. Dragovich
Peter S. Dragovich